Mustafa Özdoğan

New Capabilities

Commentary attributed to him could not be confirmed in sources reviewed.

Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on durvalumab (Imfinzi) plus chemo. That is a 25% lower risk of death in the Phase III HARMONi-GI1 trial, which Akeso presented at the ESMO 2026 Presidential Symposium in Madrid on October 25.

Updated Oct 27